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Background: In pemphigus, elucidating the disease-causing immune mechanism and
developing new therapeutic strategies are needed. In this context, the second messenger
3′,5′-cyclic adenosine monophosphate (cAMP) is gaining attention. cAMP is important in
hematological and auto-inflammatory disorders. A class of enzymes called
phosphodiesterases (PDEs) control intracellular cAMP levels. In pemphigus, cAMP
levels increase following IgG binding to Dsg3. This appears to be a mechanism to
preserve epithelial integrity.
Objectives: To determine whether apremilast, an inhibitor of the PDE4 normally used in
psoriasis, may be of benefit in the blistering skin disorder pemphigus.
Methods: Here we report of a 62 years old patient with chronic debilitating and recalcitrant
pemphigus not responding to several previous treatments, who received treatment with
apremilast over a period of 32 weeks. Desmoglein autoantibody levels were assessed by
Enzyme-linked ImmunosorbentAssay (ELISA),whereasdisease severity andquality of lifewere
assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In an attempt to
explain the effects of apremilast in pemphigus, peripheral blood mononuclear cells (PBMCs)
wereanalyzed for thedurationof treatmentby flowcytometry for thedistributionof specializedT
cell subsets. The frequencies of circulating T helper (Th) 1, Th2, Th17, Th17.1 and T follicular
helper (Tfh) 1, Tfh2, Tfh17, and Tfh17.1 were analyzed by CCR6, CXCR3, and CXCR5
expression of CD4+ T cells. Further, based on the different expressions of CXCR5, CD127,
and CD25, we analyzed the T regulatory (Treg) and T follicular regulatory (Tfreg) compartment.
Results: In response to apremilast treatment, Dsg-specific autoantibody titers
decreased, blistering ceased and lesions healed, showing a long-lasting effect. While
the frequencies of most of the Th and Tfh cell subsets remained unchanged, we observed
a continuous increase in Treg and Tfreg cell levels.
Conclusion: Our findings are encouraging and warrant extension of the beneficial effect
of PDE4 inhibition on a larger cohort of pemphigus patients.
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Meier et al. Case Report: Apremilast for Recalcitrant Pemphigus VulgarisBACKGROUND
Pemphigus with its subtypes pemphigus vulgaris (PV) and
pemphigus foliaceus (PF) is an autoimmune blistering disease that
affects skin and mucosa. Autoantibodies directed against
desmogleins (Dsg) are responsible for skin blistering (1). In PF,
patients have autoantibodies against Dsg1, whereas in PV,
circulating autoantibodies against both Dsg3 and Dsg1 are
present. Dsg are constitutive parts of desmosomes, protein
complexes responsible for keratinocyte adhesion. Binding of Dsg
by autoantibodies results in loss of cell adhesion and acantholysis
(1). PV is clinically characterized by oral and cutaneous erosions,
ranging from fragile cutaneous bullae to strongly debilitating
erosions of the nasopharyngeal region (1). Treatment guidelines
recommend systemic corticosteroids in combination with
immunosuppressive agents such as azathioprine or mycophenolate
mofetil. A recently approved therapeutic for pemphigus is theCD20-
targetingmonoclonal antibody rituximab,which depletes pre-B- and
mature B-lymphocytes. Other treatments such as methotrexate,
cyclophosphamide, dapsone, intravenous immunoglobulins or
immunoapheresis are third line options (2). The aforementioned
treatments have improved the prognosis, but adverse effects and
complications especially from long-term immunosuppressive
therapies still contribute to morbidity and mortality. Unraveling
the pathogenicmechanisms helps to identify new therapeutic targets
in pemphigus. Examples are inhibitors of Bruton’s kinase
(NCT03762265) or the development of a chimeric T cell antigen
receptor targeting autoreactive B cells (3, 4). Phosphodiesterases
(PDEs) are a family of enzymes (PDE1 to 11), which are capable of
degrading cAMP intracellularly (5). In the setting of inflammatory
skin diseases, PDE4 seems to be the most relevant subtype since it is
widely expressed in the immune, endothelial, and epithelial cells (5).
Binding of IgG to Dsg3 is a cardinal point for disease onset in
pemphigus. This process causes steric hindrance and most
importantly, activation of different signaling pathways. IgG
binding to Dsg3 activates p38MAPK, Src, and cAMP signaling
pathways (6, 7), whereas, in the cutaneous restricted PF, binding
of IgG to Dsg1 exerts its pathogenic effect in in an Erk-, p38MAPK-
and PKC-dependent fashion (7). As reported in experimental
models, interference with these pathways can prevent development
of disease (6). According to these experimental findings, here weFrontiers in Immunology | www.frontiersin.org 2report that the PDE4 inhibitor (PDE4i) apremilast results in
cessation of blistering in PV in humans.CASE PRESENTATION
Here we report the case of a 62-year-old woman with chronic, non-
responsive PV, successfully treated over a period of 32 weeks with
apremilast 30 mg twice daily. PV diagnosis was made in 2015 by
clinical appearance and further confirmed by laboratory diagnostics.
The patient presented with extensive painful erosions of the oral
cavity (Figure 1). At the time of the initial consultation, histology
showed suprabasal loss of epidermal adhesion and acantholysis.
Direct immunofluorescence demonstrated typical intercellular IgG
deposition within the epidermis. Enzyme-linked immunosorbent
assays (ELISAs) were positive for anti‐Dsg1 and anti‐Dsg3
autoantibodies. Previous therapies adopted over the years with
azathioprine, mycophenolate mofetil, dapsone, and intravenous
immunoglobulins had failed. Repeated attempts to reduce the dose
of systemic steroids below 20 to 30 mg prednisone equivalent were
not successful, and tapering was linked to the reappearance of
painful and severe oral erosions. Lastly, a therapy with rituximab
2× 1,000 mg in combination with mycophenolat mofetil and
prednisone was of no clinical benefit. Due to the exhaustion of
existing treatment options and based onpreclinical data from in vitro
and in vivo models suggesting that PDE4 inhibition may help to
control autoantibody-mediated disorders (7–9) apremilast 30 mg
twice a day (standard psoriasis regimen) was initiated as add-on
therapy to 20 mg prednisone and 2 g mycophenolat mofetil




The presence of IgG autoantibodies againstDsg1 orDsg3 in patient’s
sera was evaluated by anti-Dsg1- and anti-Dsg3-ELISA according to
the manufacturer’s protocol (Euroimmun, Lübeck, Germany).FIGURE 1 | Clinical presentation of the patient’s oral cavity at baseline, at weeks 12, 24, and 32 during apremilast treatment. The medication regimen at baseline
and at indicated time points is shown.October 2020 | Volume 11 | Article 588315
Meier et al. Case Report: Apremilast for Recalcitrant Pemphigus VulgarisFlow Cytometric Analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from
citrate-phosphate-dextrose-adenine (CPDA)-containing
peripheral blood samples by density gradient centrifugation
using lymphocyte separation medium (Capricorn Scientific,
Ebsdorfergrund, Germany) and stained for flow cytometry with
the following monoclonal antibodies:CXCR3-BV421 (G025H7),
CD4-BV510 (RPA-T4), CD45RA-FITC (HI100), CD3-PerCP-
Cy5.5 (SK7), CXCR5-PE (J252D4), CCR6-APC (G034E3),
CD127-PE-Dazzle/Texas Red (A019D5), CD25-PE-Cy7 (M-
A251), CD19-FITC (HI), CD24-PerCP-Cy5.5 (ML5), CD27-PE-
Cy7 (M-T271), CD38-BV650 (HB-7). Cells were analyzed using
BD FACS LSR II (BD Biosciences, San Jose, USA).
Laboratory Investigations
Treatment with apremilast led to a rapid and meaningful
decrease in disease activity as determined by a reduction of the
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS)
score from 38 to 0 and a suppression of anti-Dsg1 and anti-
Dsg3 autoantibody levels in serum (Figures 2A, B).
Concomitantly, the patient showed an improvement in quality
of life. The clinical improvement due to apremilast treatment
allowed for reduction of the prednisone dose below 20 mg for the
first time, and finally, a reduction to 5 mg daily maintenance dose
was tolerated without worsening of symptoms (Figure 1).
During treatment with apremilast we performed an
immunological monitoring of the effects on peripheral
circulating T cells by cell surface staining and flow cytometric
analysis as reported elsewhere (10). Based on the surface
expression of chemokine receptors we followed the levels of T
helper (Th) and T follicular helper (Tfh) cell subsets with type 1,
2, 17, and 17.1 profiles in the circulation (Figures 3A–C) (10).
Additionally, we monitored levels of circulating T regulatory
(Treg) and T follicular regulatory (Tfreg) cells (Figure 3D). At
baseline, we detected dominant Th17 (40% of total Th cells) and
Tfh17.1 (45% of total Tfh cells) cell subsets (Figures 3B, C).
However, we did not observe meaningful changes in the
distribution of type 1, 2, 17 or 17.1 Th or Tfh cell subsets over
time. Remarkably, we found an increase in circulating Treg and
Tfreg cell subsets throughout treatment with apremilast. The
proportion of Treg and Tfreg cells increased continuously duringFrontiers in Immunology | www.frontiersin.org 3the 30-week treatment period (from ~9% to ~17% and 7.5% to
15%, respectively) (Figure 3D).DISCUSSION
Initially introduced in the setting of neoplastic malignancies (11),
inhibition of PDE4 appears to be a successful way of managing
several inflammatory skin diseases. Though approved only for
plaque psoriasis, psoriatic arthritis and Behcet’s disease, off-label
reports with limited patient numbers suggest efficacy in discoid
lupus erythematosus, atopic dermatitis, pytiriasis rubra pilaris, and
generalized granuloma anulare. PDE4i seems to be effective in the
management of laminin g-1 pemphigoid as reported in an
individual with concomitant psoriasis and in a preclinical model
of epidermolysis bullosa acquisita (8, 12). Both are blistering
disorders with skin fragility, driven by autoantibodies against
laminin g-1 and collagen VII, respectively. In vitro, co-culture of
keratinocytes with Dsg3 autoantibodies led to an increase of cAMP
levels and impaired p38MAPK activation. Interfering with
intracellular cAMP levels may be a strategy to protect epidermal
integrity (9). In addition to effects on epithelial cells, apremilast may
exert immunomodulatory effects. The accumulation of cAMP by
PDE4 inhibition activates protein kinase A, and this decreases the
expression of pro-inflammatory mediators such as IL-17 or IFN-g
(13, 14). Furthermore, PDE4i promotes regulatory T cells and
regulatory IL-10-producing B cells (15, 16). In line with this, our
flow cytometry analysis of peripheral T cells demonstrated a
consistent increase in Treg and Tfreg cells during PDE4
inhibition, while autoantibody levels decreased (Figure 3D). Since
Tfh cells promote B cell mediated autoantibody production, a
mechanism that seems to be relevant in pemphigus (17, 18),
increasing Treg/Tfreg numbers may exert an inhibitory effect on
Tfh and B cell activity (19). On the contrary, we could not observe
an effect of apremilast on the Th and Tfh inflammatory subsets,
suggesting that dampening of the inflammatory process may be due
to overactivation of the regulatory compartment.
Taken together, our findings on a patient with pemphigus
treated with the PDE4i apremilast as add-on therapy to
background mycophenolat mofetil 2 g daily and prednisolone
5 mg, shows that PDE4 inhibition is a safe and effective novelA B
FIGURE 2 | (A) Anti-desmoglein (Dsg)1 and -Dsg3 autoantibody levels during apremilast treatment (32 weeks). Serum autoantibodies were determined by Enzyme-
linked Immunosorbent Assays ELISA (Euroimmune, Lübeck, Germany). (B) Clinical efficacy of apremilast treatment as assessed by the Autoimmune Bullous Skin
Disorder Intensity Score (ABSIS).October 2020 | Volume 11 | Article 588315
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R6, and CXCR3 by flow cytometry (A–C). Levels of Treg/Tfreg cells were determined by cell surface











































FIGURE 3 | Longitudinal assessment of the patient’s circulating T follicular helper (Tfh) (A, B), T helper (A, C) a
apremilast treatment. CD45RA−CD4+ memory T cells were analyzed for their surface expression of CXCR5, CC
staining for CXCR5, CD25, and CD127 of CD45RA–CD4+ memory T cells (A, D). Peripheral blood was stained
cytometry (BD LSR II and flowjo Software).
Meier et al. Case Report: Apremilast for Recalcitrant Pemphigus Vulgaristreatment option. Meaningful clinical improvement and
suppression of autoantibodies were achieved 12 weeks after
PDE4i treatment was initiated. The clinical and serological
response was accompanied by an increase of peripheral Treg
and Tfreg cells over a treatment period of 30 weeks. Future
studies are needed to establish apremilast as an add-on small
molecular therapeutic in treatment-resistant pemphigus.DATA AVAILABILITY STATEMENT
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